Please login to the form below

Not currently logged in

Pfizer to acquire Biohaven in deal worth over $11bn

The deal will expand Pfizer’s Internal Medicine pipeline


Pfizer has announced it will acquire Biohaven Pharmaceutical, the makers of a US-approved dual-acting migraine therapy.

The therapy is approved for both acute treatment and episodic prevention of migraine in adults, both of which remain areas of considerable unmet need.

In addition to Nurtec ODT – known as Rimegepant and Vydura in the EU – the transaction involves the acquisition of Biohaven’s other calcitonin gene-related programmes.

This includes Zavegepant, an intranasal spray for the acute treatment of migraine which is on track for acceptance in the US and which may also become available as a gel in the future.

“Today’s announcement builds on our legacy of delivering breakthroughs for patients living with complex pain disorders and diseases that disproportionately impact women,” said Nick Lagunowich, global president at Pfizer Internal Medicine. “Nurtec ODT, which is already the number one prescribed migraine medicine in its class in the US, coupled with Biohaven’s CGRP pipeline, offers hope for patients suffering from migraine worldwide.”

“We are excited to announce Pfizer’s proposed acquisition of Biohaven. Pfizer’s capabilities will accelerate our mission to deliver our migraine medicines to even more patients, while the new R&D company is well positioned to bring value to patients and shareholders by focusing on our innovative pipeline for neurological and other disorders,” said Vlad Coric, chairman and CEO of Biohaven.

Spin-out, ‘New Biohaven’, will operate under the Biohaven name and will be led by Vlad Coric. It will also include other members of the current management team.

The boards of directors at both Biohaven and Pfizer have unanimously approved the transaction, resulting in Pfizer obtaining all outstanding shares relating to Biohaven which are not already owned by Pfizer.

Pfizer’s acquisition of Biohaven is subject to the completion of the New Biohaven element of the deal and customary closing conditions, including receipt of regulatory approvals and approval by Biohaven’s shareholders.

It is expected that the transaction will close by early 2023.

Article by
John Pinching

11th May 2022

From: Research, Sales, Healthcare



Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....